Saturday 17 October 2026
Export DRMA’s income statement to Excel — free account
Dermata Therapeutics, Inc.
DRMA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.4% and free cash flow grew 9.99%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.05
−5.49%
Follow DRMA
Dermata Therapeutics, Inc. (DRMA) P/E ratio
Dermata Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.3× (July 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.3×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. | n/m |
| LGVN Longeveron Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | 0.0× |
| AZTR Azitra, Inc. compare | 1.0× |
| PCSA Heatwurx Inc. compare | 1.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)